Cover Image

O11 Hepatitis C: stigma indicators and patient reported outcome measures for DAA treatment

Saved in:

Bibliographic Details
Main Authors:	C. Treloar (Author), E. Cama (Author), L. Brener (Author), M. Hopwood (Author), J. Dewit (Author), A. Madden (Author), J. Neale (Author)
Format:	Book
Published:	Elsevier, 2017-08-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Beyond cure: patient reported outcomes of hepatitis C treatment among people who inject drugs in Australia
by: Annie Madden, et al.
Published: (2018)

Responding to a national policy need: development of a stigma indicator for bloodborne viruses and sexually transmissible infections
by: Timothy R. Broady, et al.
Published: (2018)

Health workers' perspectives of hepatitis B-related stigma among Aboriginal and Torres Strait Islander people in New South Wales, Australia
by: Elena Cama, et al.
Published: (2023)

Correction: Health workers' perspectives of hepatitis B-related stigma among Aboriginal and Torres Strait Islander people in New South Wales, Australia
by: Elena Cama, et al.
Published: (2024)

Management of Hepatitis C Infection with Direct Action Antiviral Drugs (DAA)**
by: Roberto Focaccia, et al.
Published: (2015)

Hepatitis C virus infection: Epidemiology in Egypt, Pathophysiology and DAAs-based therapy
by: Heba Elbadawy, et al.
Published: (2021)

A universal precautions approach to reducing stigma in health care: getting beyond HIV-specific stigma
by: Carla Treloar, et al.
Published: (2022)

Understanding stigma and attitudes towards hepatitis B among university students in Australia of Chinese and Vietnamese background
by: Loren Brener, et al.
Published: (2024)

P38 Hepatitis NSW's specialised counselling service: professional support for people undertaking DAA treatment for viral hepatitis C
by: L. Pesa, et al.
Published: (2017)

A piece of the jigsaw of primary care: health professional perceptions of an integrated care model of hepatitis C management in the community
by: Treloar C, et al.
Published: (2014)

DAA - directly acting antivirals - as a new, more efficient solution of the chronic hepatitis C treatment and theirs various application.
by: Kamila Abram, et al.
Published: (2023)

Evaluation of the Deadly Liver Mob program: insights for roll-out and scale-up of a pilot program to engage Aboriginal Australians in hepatitis C and sexual health education, screening, and care
by: Carla Treloar, et al.
Published: (2018)

P29 Treating hepatitis C virus infection (HCV) with direct acting antivirals (DAAs) through the existing infrastructure of opioid agonist therapy (OAT)
by: J. Keats, et al.
Published: (2017)

On-site testing and case management to improve hepatitis C care in drug users: a prospective, longitudinal, multicenter study in the DAA era
by: Dana Busschots, et al.
Published: (2021)

Experiences of diagnosis, care and treatment among Aboriginal people living with hepatitis C
by: Loren Brener, et al.
Published: (2016)

Vertical transmission of hepatitis C: towards universal antenatal screening in the era of new direct acting antivirals (DAAs)? Short review and analysis of the situation in Switzerland
by: Karoline Aebi-Popp, et al.
Published: (2016)

The continuum of hepatitis C care for criminal justice involved adults in the DAA era: a retrospective cohort study demonstrating limited treatment uptake and inconsistent linkage to community-based care
by: Karli R. Hochstatter, et al.
Published: (2017)

An evolutionary concept analysis: stigma among women living with hepatitis C
by: Chelsea Masterman, et al.
Published: (2024)

Anti-HCV DAA are needed whatever liver fibrosis is. The cons
by: Pablo Barreiro
Published: (2016)

Anti-HCV DAA are needed whatever liver fibrosis is. The pros
by: Albert Tran
Published: (2016)

O12 Australia could meet the WHO HCV elimination targets if the current rollout of DAA treatment is continued
by: A.J. Kwon, et al.
Published: (2017)

The effect of APN, hs-CRP and APN/hs-CRP in periodontitis with DAA
by: Rui Cheng, et al.
Published: (2023)

Updated View on Kidney Transplant from HCV-Infected Donors and DAAs
by: Fabrizio Fabrizi, et al.
Published: (2021)

Virological impact of HCV elimination with DAAs in the HIV reservoir in HIV/HCV patients
by: M. Coiras, et al.
Published: (2019)

Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update
by: Hrvoje Roguljic, et al.
Published: (2021)

P66 A year of living safely: 12 months of DAA treatment in Canberra's prison system
by: J. Wenke, et al.
Published: (2017)

P52 'Behind closed doors, no one sees, no one knows': stigma and treatment as prevention in prison
by: J. Rance, et al.
Published: (2017)

P28 Queensland injectors health network (QuIHN) treatment management program (TMP): hepatitis C virus (HCV) direct acting antivirals (DAA) full access for people who inject drugs
by: R. Kavanagh, et al.
Published: (2017)

Peer-facilitated treatment access for hepatitis C: the Live Hep C Free project
by: Julia A. Silano, et al.
Published: (2022)

IMPLEMENTASI KONSEP TAâ€™DÄªB DALAM PENDIDIKAN ISLAM UNTUK MEWUJUDKAN SISWA BERKARAKTER
by: Maria Ulfah
Published: (2015)

O9 Progress towards elimination: rapid uptake of HCV treatment among people who inject drugs following broad access to DAA therapies
by: J. Iversen, et al.
Published: (2017)

Hepatitis C Treatment Outcomes in Kigali, Rwanda
by: S. Taylor, et al.
Published: (2016)

O4 Outcomes of treatment for hepatitis C virus infection in the prison setting
by: T. Papaluca, et al.
Published: (2017)

IMPLEMENTASI KONSEP TAâ€™DÄªB DALAM PENDIDIKAN ISLAM UNTUK MEWUJUDKAN SISWA YANG BERKARAKTER
by: Maria Ulfah
Published: (2011)

Epidemiological and economic evaluations according to DAA treatment access: an interim evaluation based on PITER cohort data
by: Stefano Vella, et al.
Published: (2018)

Access to free DAAs for people who inject drugs: is it sufficient to increase the update of HCV treatment by PWIDs?
by: Maka Gogia, et al.
Published: (2018)

A policy analysis exploring hepatitis C risk, prevention, testing, treatment and reinfection within Australia's prisons
by: Lise Lafferty, et al.
Published: (2018)

Cognitive dissonance in tuberculosis stigma: A mixed methods analysis of tuberculosis stigma measurement in South Africa.
by: Alanna J Bergman, et al.
Published: (2024)

O6 Incidence of hepatitis C virus infection in two maximum-security prisons in New South Wales, Australia: the StoP-C study
by: B. Hajarizadeh, et al.
Published: (2017)

Adapting the Opening Minds Stigma Scale for Healthcare Providers to Measure Opioid-Related Stigma
by: Ashley Cid, et al.
Published: (2024)